Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 6/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.51 |
| ▸ | NQO2 | P16083 | 4/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.48 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825083 | 0.91 | MTNR1A (0.54) | MTNR1BMTNR1ANQO2 | |
| SCHEMBL31613070 | 0.89 | HSD17B10 (0.49) | — | |
| SCHEMBL30695338 | 0.87 | SIRT1 (0.56) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL1844201 | 0.87 | SIRT1 (0.56) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL1844488 | 0.87 | SIRT1 (0.56) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL1842659 | 0.87 | SIRT1 (0.56) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| Hydrochloric Acid SCHEMBL1846869 | 0.86 | SIRT1 (0.55) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL5847603 | 0.86 | MTNR1A (0.54) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL1846866 | 0.86 | MTNR1B (0.52) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL31613077 | 0.83 | MTNR1A (0.52) | MTNR1BMTNR1ANQO2C5AR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| EP-2205573-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009043780-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | claimed |
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | AR, NAT1, TBXA2R | MTNR1B 87/4885MTNR1A 36/4885NQO2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.